Evidence-based screening and treatment options for pulmonary arterial hypertension in connective tissue diseases
Patients with connective tissue disease are at a higher risk for developing PAH, for example an estimated 5-12% of scleroderma patients will develop PAH. Furthermore, the prognosis is poor for these patients; over half of patients with PAH-CTD will die within 5 years of diagnosis.
During this webinar we will discuss the importance of regular PAH screening for scleroderma spectrum patients and the best care pathways for these patients.
- Dinesh Khanna
- Janet Pope
- To highlight the importance of screening for PAH in scleroderma patients
- To discuss the clinical management of PAH-CTD patients, with a focus on the benefit of early treatment initiation and combination therapy